Reasonable construction of a unique near-infrared fluorescent probe with improved performance for imaging β-galactosidase in living cells and in vivo
Reasonable construction of a unique near-infrared fluorescent probe with improved performance for imaging β-galactosidase in living cells and in vivo
复制标题
合理构建独特的近红外荧光探针，提高活细胞和体内β-半乳糖苷酶成像性能
DOI：
10.1016/j.dyepig.2022.110769
复制
发表时间：
2022
影响因子：
4.5
通讯作者：
Youyu Zhang
中科院分区：
文献类型：
--
作者：
Zile Zhou;Xiao Pang;Cong Fang;Haitao Li;Biao Gu;Youyu Zhang
β-半乳糖苷酶与原发性卵巢癌关系密切，在转移性卵巢癌中高表达。因此，建立一种有效的β-gal原位检测方法，对卵巢癌的进一步研究具有重要意义。受近红外（NIR）荧光成像的优点启发，设计了一种改进的近红外荧光发射和检测性能的DCM-CHO-βgal荧光检测系统，使用结构改性的二氰基苯并吡喃衍生物DCM-CHO-β galcan对β-gal的响应时间短（<20 min），在665 nm处荧光增强近40倍。gal范围为0.2 - 3 U/mL，检测限低（3.15 × 10− 5 U/mL），在存在其他可能干扰的情况下可以选择性地检测β-gal。鉴于DCM-CHO-β gal优良的光学、分析性能和良好的生物相容性，将其应用于卵巢癌细胞和斑马鱼内源性β-gal的可视化研究，为深入研究β-gal在β-gal相关疾病中的作用提供了有力工具。
β-Galactosidase is closely related to primary ovarian cancer and highly expressed in metastatic ovarian cancer. Therefore, the development of effective tool for in situ detectingβ-gal is urgently needed for further studies in ovarian cancer. Inspired by the advantages of near-infrared (NIR) fluorescence imaging, a NIR fluorescent probe (DCM-CHO-βgal) with improved near-infrared fluorescence emission and detection performance was reasonably designed for the quantification and visualization ofβ-gal, employing structurally modified dicyanobenzopyran derivative (DCM-CHO-OH) as fluorophore.DCM-CHO-βgalshowed a rapid response (<20 min) towardsβ-gal accompanied by nearly 40-fold fluorescence enhancement at 665 nm.DCM-CHO-βgalcan quantitatively detectβ-gal ranging from 0.2 to 3 U/mL with a low detection limit (3.15 × 10−5U/mL), and can selectively detectβ-gal in the presence of other possible interferences. In view of excellent optical, analytical performance and good biocompatibility,DCM-CHO-βgalwas applied to the visualization of endogenousβ-gal in ovarian cancer cells and zebrafish, which provided a powerful tool for the in-depth study of the role of β-gal in β-gal-related diseases.